This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Ebola glycoprotein (GP1)-based vaccine to prevent Ebola infection	<p>An <i>in vitro</i> and mouse study suggests a vaccine based on a GP1 fusion protein could help protect against Ebola infection. The fusion protein consisted of a GP1 antigen linked to a mAb fragment that recognized an epitope on GP1. In mice, the fusion protein plus a toll-like receptor 3 (TLR3) agonist led to 80% protection from lethal Ebola challenge compared with a TLR3 agonist alone, which showed no protection. Next steps include optimizing the vaccine formulation and running additional safety studies.</p> <p>SciBX 5(2); doi:10.1038/scibx.2012.57 Published online Jan. 12, 2012</p>	Patent and licensing status undisclosed	<p>Poolcharoen, W. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Dec. 5, 2011; doi:10.1073/pnas.1117715108 Contact: Melissa M. Herbst-Kralovetz, The University of Arizona, Phoenix, Ariz. e-mail: mherbst1@email.arizona.edu Contact: Charles J. Arntzen, Arizona State University, Tempe, Ariz. e-mail: charles.arntzen@asu.edu</p>